New CRC Screening Recommendations Posted for Adults Aged 45 to 75 Years

October 30, 2020

A draft recommendation statement was published by the United States Preventive Services Task Force stating that screening for colorectal cancer should start at the age of 45, according to a press release from the Task Force Bulletin.

3-Month CAPOX Regimen Appears Less Toxic Than 6-Month Treatment in CRC

October 30, 2020

Results of a randomized phase 3 trial demonstrated that the 3-month regimen of adjuvant combination therapy caused significantly less grade 2 or more peripheral sensory neuropathy than the 6-month regimen as treatment of patients with high-risk stage II colorectal cancer, while not affecting the 3-year disease-free survival rate, according to a report in the Annals of Oncology.

Countless Options to Improve Future Outcomes in Subgroups of Patients With GU Cancers

October 30, 2020

In genitourinary cancers, presentation of subgroup analysis data from large randomized clinical trials demonstrated findings that will change practice for oncologists who treat patients with prostate cancer, bladder cancer, and renal cell carcinoma.

FDA Approves First Companion Diagnostic Test for Expanded EGFR TKIs in NSCLC

October 30, 2020

The FDA has granted approval to the cobas EGFR Mutation Test v2 as a companion diagnostic for EGFR tyrosine kinase inhibitors as treatment of patients with EGFR-mutant non–small cell lung cancer, which is the first assay approved for this indication.

Immunotherapy Combinations Appear Efficacious in Long-Term Follow-up of Advanced RCC

October 30, 2020

In an interview with Targeted Oncology, Laurence Albiges, MD, PhD, discussed the updated findings for the combination of nivolumab and ipilimumab as treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma.

Crizotinib Activity in MET-Altered Non-Small Cell Lung Cancer Undetermined

October 29, 2020

While the remarkable activity of crizotinib as treatment of patients with ROS1 fusion-positive advanced non–small cell lung cancer was confirmed in a recent systemic review and meta-analysis, the efficacy of this small molecular inhibitor remains unknown in patients with MET-altered disease.

Should Frontline Myeloma Treatment Include a 3- or 4-Drug Regimen?

October 29, 2020

Shaji K. Kumar, MD, addresses an important unanswered question that remains in the treatment landscape of newly diagnosed multiple myeloma, which is whether 3- or 4-drug regimens should be used in the frontline setting.

Brander Details Different Therapies and Modalities for Treatment of CLL in the Second Line

October 29, 2020

During a Targeted Oncology Case Based Peer Perspectives event, Danielle Brander, MD, assistant professor of Medicine at Duke Cancer Institute in Durham, NC, discussed options for treating a 53-year-old female patients with chronic lymphocytic leukemia.